TIDMMEDG 
 
RNS Number : 1331K 
Medgenics Inc 
14 April 2010 
 

14 April 2010 
                                 Medgenics, Inc 
 
                         ('Medgenics' or the 'Company') 
 
                      Change of Name of Nominated Adviser 
 
 
The Company announces that Blomfield Corporate Finance Limited, the Company's 
Nominated Adviser has changed its name to Religare Capital Markets (UK) Limited 
- trading as Religare Capital Markets. 
 
For further information: 
 
Andrew Pearlman                                               +972 4 902 8900 
CEO 
Medgenics, Inc 
 
James Pinner / Derek Crowhurst                          +44 207 444 0800 
Religare Capital Markets 
www.religarecm.com 
 
 
Notes to Editors: 
About Medgenics: 
Medgenics is a clinical-stage biopharmaceutical Company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. Biopumps are made 
using needle biopsies taken from the lower layer of the patient's skin under 
local anaesthetic, and processed during 10-14 days to become 30 mm long tissue 
biofactories producing the required protein.  The requisite number of Biopumps 
are injected under the patient's skin to provide sustained protein production 
and delivery for many months. The Company is developing the Biopump to provide 
substantially greater safety and reliability in protein treatment in a more cost 
effective manner than experienced with the existing injected protein therapies. 
Medgenics currently has three products in development based on this technology 
and addressing the indications of: 
- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Haemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effective anaemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anaemia, Hepatitis-C, and 
Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by 2010. Other potential 
applications of Biopumps producing various proteins include multiple sclerosis, 
arthritis, pediatric growth hormone deficiency, obesity, and diabetes. 
<ENDS> 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCGGUUACUPUGAW
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Medgenics(Regs) Charts.